Grace Therapeutics (GRCE)
Developing alternative-delivery therapies from established drugs.
$2.14
Pre-market0.00 (0.00%)
At close$2.14(+1.90%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions36 holders · as of Mar 31, 2026 | 26.20% | 4.26M shares | |
| Insiders1 holder · as of May 8, 2025 | 8.13% | 1.32M shares | |
| Strategic holders2 holders · as of Aug 19, 2026 | 27.51% | 4.48M shares | |
| Otherremainder | 38.16% | 6.21M shares |
16.27M company shares as of Sep 2, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (21.04M in the company's Sep 3, 2026 report, 16.27M elsewhere); stakes use the report.
Institutions13F, as of Mar 31, 2026
36 holders · 4.26M shares · 19 new positions · 25 increased · 4 reduced · 6 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Cerity Partners LLC | 849.1K | 5.22% | +426.3K | May 15, 2026 |
| Eversept Partners, LP | 756.6K | 4.65% | +756.6Knew | May 15, 2026 |
| Nantahala Capital Management, LLC | 728.2K | 4.47% | −450.0K | May 15, 2026 |
| Bank of America Corp /DE/ | 494.7K | 3.04% | +25 | May 18, 2026 |
| Vanguard Capital Management LLC | 401.7K | 2.47% | +401.7Knew | May 15, 2026 |
| Renaissance Technologies LLC | 243.9K | 1.50% | +114.1K | May 14, 2026 |
| Jane Street Group, LLC | 167.1K | 1.03% | +167.1Knew | May 12, 2026 |
| Citadel Advisors LLC | 98.7K | 0.61% | +56.4K | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Opaleye Management Inc. | 13.07% | 2.75M | 13G | Aug 7, 2026 ↗ |
| Nantahala Capital Management, LLC | 9.99% | 1.59M | 13G | Feb 13, 2026 ↗ |
| ADAR1 Capital Management, LLC | 9.90% | 1.72M | 13G | May 15, 2026 ↗ |
| Hirschman Orin | 9.90% | 1.32M | 13G | May 8, 2025 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 14, 2026 | Opaleye Management Inc.10 percent owner | Purchase | 11,608 | $2.09 | 2,760,000 |
CongressHouse and Senate disclosures
Not reported.
